208 related articles for article (PubMed ID: 28363186)
21. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.
Chen MK; Hung HF; Duffy S; Yen AM; Chen HH
J Eval Clin Pract; 2011 Dec; 17(6):1050-8. PubMed ID: 21679279
[TBL] [Abstract][Full Text] [Related]
22. Organised screening for cervical cancer in France: a cost-effectiveness assessment.
Barré S; Massetti M; Leleu H; De Bels F
BMJ Open; 2017 Oct; 7(10):e014626. PubMed ID: 28988162
[TBL] [Abstract][Full Text] [Related]
23. Cervical cancer screening among HIV-infected women: an economic evaluation in a middle-income country.
Vanni T; Luz PM; Grinsztejn B; Veloso VG; Foss A; Mesa-Frias M; Legood R
Int J Cancer; 2012 Jul; 131(2):E96-104. PubMed ID: 21964797
[TBL] [Abstract][Full Text] [Related]
24. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST).
Mayrand MH; Duarte-Franco E; Coutlée F; Rodrigues I; Walter SD; Ratnam S; Franco EL;
Int J Cancer; 2006 Aug; 119(3):615-23. PubMed ID: 16572425
[TBL] [Abstract][Full Text] [Related]
25. Cost effectiveness of human papillomavirus-16/18 genotyping in cervical cancer screening.
Huh WK; Williams E; Huang J; Bramley T; Poulios N
Appl Health Econ Health Policy; 2015 Feb; 13(1):95-107. PubMed ID: 25385310
[TBL] [Abstract][Full Text] [Related]
26. [Cervical cancer screening with primary HPV-DNA test in the Local Health Authority 2 of Savona (Liguria Region, Northern Italy): a population-based study].
Depetrini E; Bonelli L; Ardoino S; Cirucca MC; Contin R; De Leonardis D; Errigo V; Lugani A; Franco A; Pastorino A; Carrozzi G; Venturino E
Epidemiol Prev; 2016; 40(3-4):171-8. PubMed ID: 27436250
[TBL] [Abstract][Full Text] [Related]
27. History of high-risk HPV and Pap test results in a large cohort of patients with invasive cervical carcinoma: experience from the largest women's hospital in China.
Tao X; Griffith CC; Zhou X; Wang Z; Yan Y; Li Z; Zhao C
Cancer Cytopathol; 2015 Jul; 123(7):421-7. PubMed ID: 25955972
[TBL] [Abstract][Full Text] [Related]
28. Interpretation of p16(INK4a) /Ki-67 dual immunostaining for the triage of human papillomavirus-positive women by experts and nonexperts in cervical cytology.
Allia E; Ronco G; Coccia A; Luparia P; Macrì L; Fiorito C; Maletta F; Deambrogio C; Tunesi S; De Marco L; Gillio-Tos A; Sapino A; Ghiringhello B
Cancer Cytopathol; 2015 Apr; 123(4):212-8. PubMed ID: 25534957
[TBL] [Abstract][Full Text] [Related]
29. Triage of women with negative cytology and positive high-risk HPV: an analysis of data from the SHENCCAST II/III studies.
Goodrich SK; Pretorius RG; Du H; Wu R; Belinson JL
J Low Genit Tract Dis; 2014 Apr; 18(2):122-7. PubMed ID: 24270196
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: a systematic review commissioned by the German Federal Ministry of Health.
Mühlberger N; Sroczynski G; Esteban E; Mittendorf T; Miksad RA; Siebert U
Int J Technol Assess Health Care; 2008; 24(2):184-92. PubMed ID: 18400122
[TBL] [Abstract][Full Text] [Related]
31. The comparative and cost-effectiveness of HPV-based cervical cancer screening algorithms in El Salvador.
Campos NG; Maza M; Alfaro K; Gage JC; Castle PE; Felix JC; Cremer ML; Kim JJ
Int J Cancer; 2015 Aug; 137(4):893-902. PubMed ID: 25639903
[TBL] [Abstract][Full Text] [Related]
32. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A
BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934
[TBL] [Abstract][Full Text] [Related]
33. Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era.
Tota J; Mahmud SM; Ferenczy A; Coutlée F; Franco EL
Sex Health; 2010 Sep; 7(3):376-82. PubMed ID: 20719230
[TBL] [Abstract][Full Text] [Related]
34. Prevalence and determinants of cervical cancer screening with a combination of cytology and human papillomavirus testing.
Fokom Domgue J; Cunningham SA; Yu RK; Shete S
Ann Epidemiol; 2019 Aug; 36():40-47. PubMed ID: 31320153
[TBL] [Abstract][Full Text] [Related]
35. HPV self-sampling or the Pap-smear: a randomized study among cervical screening nonattenders from lower socioeconomic groups in France.
Sancho-Garnier H; Tamalet C; Halfon P; Leandri FX; Le Retraite L; Djoufelkit K; Heid P; Davies P; Piana L
Int J Cancer; 2013 Dec; 133(11):2681-7. PubMed ID: 23712523
[TBL] [Abstract][Full Text] [Related]
36. [New strategies for the prevention and control of cervical cancer in Chile.].
Ferreccio C
Salud Publica Mex; 2018; 60(6):713-721. PubMed ID: 30699276
[TBL] [Abstract][Full Text] [Related]
37. The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies.
Holmes J; Hemmett L; Garfield S
Eur J Health Econ; 2005 Mar; 6(1):30-7. PubMed ID: 15682286
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of high-risk human papillomavirus and abnormal pap smears in female sex workers compared to the general population in Antwerp, Belgium.
Vorsters A; Cornelissen T; Leuridan E; Bogers J; Vanden Broeck D; Benoy I; Goossens H; Hens N; Van Damme P
BMC Public Health; 2016 Jun; 16():477. PubMed ID: 27266509
[TBL] [Abstract][Full Text] [Related]
39. Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany.
Sroczynski G; Schnell-Inderst P; Mühlberger N; Lang K; Aidelsburger P; Wasem J; Mittendorf T; Engel J; Hillemanns P; Petry KU; Krämer A; Siebert U
GMS Health Technol Assess; 2010 Apr; 6():Doc05. PubMed ID: 21289878
[TBL] [Abstract][Full Text] [Related]
40. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
